The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Placebo‐Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV‐1 Infection
Abstract
BACKGROUND: A vaccine is needed to prevent human immunodeficiency virus type 1 (HIV-1) infection. METHODS: A double-blind, randomized trial of a recombinant HIV-1 envelope glycoprotein subunit (rgp120) vaccine was conducted among men who have sex with men and among women at high risk for heterosexual transmission of HIV-1. Volunteers received 7 injections of either vaccine or placebo (ratio, 2 : 1) over 30 months. The primary end point was HIV-1 seroconversion over 36 months. RESULTS: A total of 5403 volunteers (5095 men and 308 women) were evaluated. The vaccine did not prevent HIV-1 acquisition: infection rates were 6.7% in 3598 vaccinees and 7.0% in 1805 placebo recipients; vaccine efficacy (VE) was estimated as 6% (95% confidence interval, -17% to 24%). There were no significant differences in viral loads, rates of antiretroviral-therapy initiation, or the genetic characteristics of the infecting HIV-1 strains between treatment arms. Exploratory subgroup analyses showed nonsignificant trends toward efficacy in preventing infection in the highest risk (VE, 43%; n=247) and nonwhite (VE, 47%; n=914) volunteers (P=.10, adjusted for multiple subgroup comparisons). CONCLUSIONS: There was no overall protective effect. The efficacy trends in subgroups may provide clues for the development of effective immunization approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A., & Landau, N. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80110-5 · Cited by 3,074
Samson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C.-M., Saragosti, S., Lapouméroulie, C., Cognaux, J., Forceille, C., et al. (1996) · Nature · doi:10.1038/382722a0 · Cited by 2,886
Survival analysis using the SAS system : a practical guide
Allison, P. D. (1995) · Medical Entomology and Zoology · Cited by 2,402
Subgroup analysis and other (mis)uses of baseline data in clinical trials
Assmann, S. F., Pocock, S. J., Enos, L. E., & Kasten, L. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02039-0 · Cited by 1,167
Applying Cox Regression to Competing Risks
Lunn, M., & McNeil, D. (1995) · Biometrics · doi:10.2307/2532940 · Cited by 975
A Gender Gap in Autoimmunity: Task Force on Gender, Multiple Sclerosis and Autoimmunity
Whitacre, C. C., Reingold, S. C., O'Looney, P. A., Blankenhorn, E., Brinley, F., Collier, E., Duquette, P., Fox, H., Giesser, B., Gilmore, W., et al. (1999) · Science · doi:10.1126/science.283.5406.1277 · Cited by 851
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
Stanberry, L. R., Spruance, S. L., Cunningham, A. L., Bernstein, D. I., Mindel, A., Sacks, S., Tyring, S., Aoki, F. Y., Slaoui, M., Denis, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011915 · Cited by 794
Wald, A., & Link, K. (2002) · The Journal of Infectious Diseases · doi:10.1086/338231 · Cited by 691
Berman, P. W., Gregory, T. J., Riddle, L., Nakamura, G. R., Champe, M. A., Porter, J. P., Wurm, F. M., Hershberg, R. D., Cobb, E. K., & Eichberg, J. W. (1990) · Nature · doi:10.1038/345622a0 · Cited by 590
Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya
Fowke, K. R., Nagelkerke, N. J., Kimani, J., Simonsen, J. N., Anzala, A. O., Bwayo, J. J., MacDonald, K. S., Ngugi, E. N., & Plummer, F. A. (1996) · The Lancet · doi:10.1016/s0140-6736(95)12269-2 · Cited by 463
Effect of Coinfection with GB Virus C on Survival among Patients with HIV Infection
Xiang, J., Wünschmann, S., Diekema, D. J., Klinzman, D., Patrick, K. D., George, S. L., & Stapleton, J. T. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003364 · Cited by 379
Gilbert, P. B., Peterson, M. L., Follmann, D., Hudgens, M. G., Francis, D. P., Gurwith, M., Heyward, W. L., Jobes, D. V., Popovic, V., Self, S. G., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/428405 · Cited by 355
Antibody-Dependent Enhancement of Infection and the Pathogenesis of Viral Disease
Morens, D. M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.3.500 · Cited by 317
HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene
Quillent, C., Oberlin, E., Braun, J., Rousset, D., Gonzalez-Canali, G., Métais, P., Montagnier, L., Virelizier, J.-L., Arenzana-Seisdedos, F., & Beretta, A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09185-x · Cited by 271
Persistent GB Virus C Infection and Survival in HIV-Infected Men
Williams, C. F., Klinzman, D., Yamashita, T. E., Xiang, J., Polgreen, P. M., Rinaldo, C., Liu, C., Phair, J., Margolick, J. B., Zdunek, D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030107 · Cited by 269
McMichael, A. J., & Hanke, T. (2003) · Nature Medicine · doi:10.1038/nm0703-874 · Cited by 240
CpG Oligodeoxynucleotides as Vaccine Adjuvants in Primates
Verthelyi, D., Kenney, R. T., Seder, R. A., Gam, A. A., Friedag, B., & Klinman, D. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.4.1659 · Cited by 199
Risk Behavior for HIV Infection in Participants in Preventive HIV Vaccine Trials: A Cautionary Note
Chesney, M. A., Chambers, D. B., & Kahn, J. S. (1997) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199712010-00007 · Cited by 141
Moore, A., McCarthy, L., & Mills, K. H. G. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00062-6 · Cited by 121
Influence of Ethnicity in the Outcome of Hepatitis C Virus Infection and Cellular Immune Response
Sugimoto, K., Stadanlick, J. E., Ikeda, F., Brensinger, C. M., Furth, E. E., Alter, H. J., & Chang, K. (2003) · Hepatology · doi:10.1053/jhep.2003.50103 · Cited by 114
Berman, P. W., Murthy, K. K., Wrin, T., Vennari, J., Cobb, E. K., Eastman, D. J., Champe, M., Nakamura, G. R., Davison, D. K., Powell, M. F., et al. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.1.52 · Cited by 109
Choice of a null distribution in resampling-based multiple testing
Pollard, K. S., & van der Laan, M. J. (2004) · Journal of Statistical Planning and Inference · doi:10.1016/j.jspi.2003.07.019 · Cited by 92
Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials.
Francis, D. P., Heyward, W. L., Popovic, V., Orozco-Cronin, P., Orelind, K., Gee, C., Hirsch, A., Ippolito, T., Luck, A., Longhi, M., et al. (2003) · PubMed · doi:10.1097/01.aids.0000050786.28043.62 · Cited by 88
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.
Francis, D. P., Gregory, T. J., McElrath, M. J., Belshe, R. B., Gorse, G. J., Migasena, S., Kitayaporn, D., Pitisuttitham, P., Matthews, T. J., Schwartz, D. H., et al. (1998) · PubMed · Cited by 73
The Highest Attainable Standard: Ethical Issues in AIDS Vaccines
Bloom, B. R. (1998) · Science · doi:10.1126/science.279.5348.186 · Cited by 62
Harro, C. D., Judson, F. N., Gorse, G. J., Mayer, K. H., Kostman, J. R., Brown, S. J., Koblin, B. A., Marmor, M. F., Bartholow, B. N., & Popovic, V. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000122983.87519.b5 · Cited by 58
Human HIV Vaccine Trials: Does Antibody-Dependent Enhancement Pose a Genuine Risk?
Burke, D. S. (1992) · Perspectives in biology and medicine · doi:10.1353/pbm.1992.0048 · Cited by 57
Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2
Amad, Z., MURTHY, K. K., Higgins, K. W., Cobb, E. K., Haigwood, N. L., Levy, J. A., & Steimer, K. S. (1995) · AIDS · doi:10.1097/00002030-199512000-00003 · Cited by 49
Biological Considerations in the Development of a Human Immunodeficiency Virus Vaccine
Nathanson, N., & Mathieson, B. J. (2000) · The Journal of Infectious Diseases · doi:10.1086/315707 · Cited by 46
Klinman, D. M., Kamstrup, S., Takeshita, F., Gürsel, M., Verthelyi, D. I., Gürsel, İ., & Ishii, K. J. (2000) · Springer Seminars in Immunopathology · doi:10.1007/s002810050027 · Cited by 42
P-value adjustments for fubgroup analyses
Bristol, D. R. (1997) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543409708835189 · Cited by 18
Cited by
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
Sanders, R. W., Derking, R., Cupo, A., Julien, J.-P., Yasmeen, A., de Val, N., Kim, H. J., Blattner, C., de la Peña, A. T., Korzun, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003618 · Cited by 935
Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., van Griensven, F., Hu, D., Tappero, J. W., Choopanya, K., & Bangkok Vaccine Evaluation Group (2006) · The Journal of Infectious Diseases · doi:10.1086/508748 · Cited by 847
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
McElrath, M. J., De Rosa, S. C., Moodie, Z., Dubey, S., Kierstead, L., Janes, H., Defawe, O. D., Carter, D. K., Hural, J., Akondy, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61592-5 · Cited by 713
Metadata
- Authors
- The rgp120 HIV Vaccine Study Group
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-03
- Volume
- 191
- Issue
- 5
- Pages
- 654-665
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2240372320
- Cited by
- 952
- References
- 31
- FWCI
- 15.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.